Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Lymphoma and Cancer Therapy
share announcement

Lymphoma and Cancer Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (15 July 2022) | Viewed by 15724

Special Issue Editor

Dr. Carla Minoia

E-Mail Website
Guest Editor
Hematology Unit-Istituto Tumori "Giovanni Paolo II", Bari, Italy
Interests: microenvironment, imaging, quality of lyfe and survivorship in lymphoproliferative neoplasms

Special Issue Information

Lymphoproliferative neoplasms represent a large spectrum of diseases, whose etiopathogenesis, clinical features, and treatment is very differentiated. In the meanwhile, we observe more frequent histotypes for which we dispose of standard therapies, as well as more rare histopathological and molecular entities, also recently identified, for which the best treatment options are in definition within clinical trials.

In this Special Issue, we aim to collect the results from clinical trials, cohort studies, case reports and reviews, on the innovative therapeutic approaches for lymphomas. We would mostly focus on rare histotypes, for example peripheral T-cell lymphomas, mantle cell lymphoma or extra-nodal lymphomas, and on forms for which the treatment is chosen based on genetic or epigenetic profiles.

Dr. Carla Minoia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lymphoma
  • target therapy
  • personalised therapy
  • genetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 626 KiB  
Article
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience
by Michele Clerico, Irene Dogliotti, Paola Ghione, Vittorio Ruggero Zilioli, Francesco Merli, Barbara Botto, Wael Al Essa, Marcella Battaglini, Daniele Grimaldi, Loretta Cervi, Simone Ragaini, Simone Ferrero, Veronica Peri, Gabriele De Luca, Alfredo Marzano and Federica Cavallo
J. Pers. Med. 2022, 12(2), 285; https://doi.org/10.3390/jpm12020285 - 15 Feb 2022
Cited by 4 | Viewed by 3142
Abstract
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-negative and anti-hepatitis B core antigen antibodies (anti-HBc) positive (past HBV infection) patients receiving immuno-chemotherapy for hematological malignancies. A higher rate of HBVr is associated with the use of [...] Read more.
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-negative and anti-hepatitis B core antigen antibodies (anti-HBc) positive (past HBV infection) patients receiving immuno-chemotherapy for hematological malignancies. A higher rate of HBVr is associated with the use of rituximab (R) in patients with past HBV infection, thus justifying an antiviral prophylaxis. In this study we evaluated the incidence of HBVr in a real-life cohort of 362 anti-HBc-positive subjects affected by non-Hodgkin lymphoma (NHL), mainly receiving lamivudine (LAM) prophylaxis (93%) and all undergoing a R-containing regimen. A retrospective, multicenter, observational study was conducted in 4 Italian Hematology Departments. The primary endpoint was the incidence of virologic (HBV DNA-positive), serologic (HBsAg-positive) and clinical (ALT increase > 3 × upper limit of normal) HBVr, which occurred in five, four and one patients, respectively, with a total HBVr rate of 1.4%. None of them had to discontinue the chemotherapy program, while two patients required a delay. Treatment-related adverse events (AEs) were reported during LAM prophylaxis in three patients (0.9%). In conclusion, this study confirms the efficacy and safety of LAM prophylaxis in anti-HBc-positive patients undergoing R-containing regimens. Full article
(This article belongs to the Special Issue Lymphoma and Cancer Therapy)
►▼ Show Figures

Figure 1

17 pages, 1910 KiB  
Article
Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia
by Irene Dogliotti, Simone Ragaini, Francesco Vassallo, Elia Boccellato, Gabriele De Luca, Francesca Perutelli, Carola Boccomini, Michele Clerico, Barbara Botto, Daniele Grimaldi, Lorella Orsucci, Simone Ferrero, Candida Vitale, Dario Ferrero, Marta Coscia and Federica Cavallo
J. Pers. Med. 2021, 11(4), 249; https://doi.org/10.3390/jpm11040249 - 30 Mar 2021
Cited by 6 | Viewed by 3232
Abstract
Background. Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated. Methods: An observational, retrospective study was carried out; patients [...] Read more.
Background. Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated. Methods: An observational, retrospective study was carried out; patients with chronic lymphocytic leukemia (CLL) or lymphoma, aged ≥ 65 years old, treated with bendamustine-based regimens in first or subsequent lines between 2010 and 2020 were considered eligible. Results: Overall, 179 patients aged ≥ 65 years were enrolled, 53% between 71 and 79 years old. Cumulative Illness Rating Scale (CIRS) comorbidity score was ≥6 in 54% patients. Overall survival (OS) at 12 months was 95% (95% confidence interval [CI]: 90–97%); after a median follow up of 50 months, median OS was 84 months. The overall response rate was 87%, with 56% complete responses; the median time to progression (TTP) was 61 months. The baseline factors affecting OS by multivariable analysis were sex, histological diagnosis, renal function, and planned bendamustine dose, while only type of lymphoma and bendamustine dose impacted on TTP. Main adverse events were neutropenia (grade ≥ 3: 43%) and infections (any grade: 36%), with 17% of patients requiring hospital admission. Conclusions: The responses to bendamustine, as well as survival, are relevant even in advanced age patients, with a manageable incidence of acute toxicity. Full article
(This article belongs to the Special Issue Lymphoma and Cancer Therapy)
►▼ Show Figures

Figure 1

13 pages, 2110 KiB  
Article
Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin’s Lymphoma Survivors
by A. Daniele, A. Guarini, S. De Summa, M. Dellino, G. Lerario, S. Ciavarella, P. Ditonno, A. V. Paradiso, R. Divella, P. Casamassima, E. Savino, M. D. Carbonara and C. Minoia
J. Pers. Med. 2021, 11(3), 215; https://doi.org/10.3390/jpm11030215 - 17 Mar 2021
Cited by 6 | Viewed by 3276
Abstract
Unhealthy lifestyle, as sedentary, unbalanced diet, smoking, and body composition change are often observed in non-Hodgkin’s lymphoma (NHL) survivors, and could be determinant for the onset of cancer treatment-induced metabolic syndrome (CTIMetS), including abdominal obesity, sarcopenia, and insulin resistance. The aim of this [...] Read more.
Unhealthy lifestyle, as sedentary, unbalanced diet, smoking, and body composition change are often observed in non-Hodgkin’s lymphoma (NHL) survivors, and could be determinant for the onset of cancer treatment-induced metabolic syndrome (CTIMetS), including abdominal obesity, sarcopenia, and insulin resistance. The aim of this study was to assess whether changes in body composition, unhealthy lifestyles and types of anti-cancer treatment could increase the risk of metabolic syndrome (MetSyn) and sarcopenia in long-term NHL survivors. We enrolled 60 consecutive NHL patients in continuous remission for at least 3 years. Nutritional status was assessed by anthropometry-plicometry, and a questionnaire concerning lifestyles and eating habits was administered. More than 60% of survivors exhibited weight gain and a change in body composition, with an increased risk of MetSyn. Univariate analysis showed a significantly higher risk of metabolic disorder in patients treated with steroids, and in patients with unhealthy lifestyles. These data suggest that a nutritional intervention, associated with adequate physical activity and a healthier lifestyle, should be indicated early during the follow-up of lymphoma patients, in order to decrease the risk of MetSyn’s onset and correlated diseases in the long term. Full article
(This article belongs to the Special Issue Lymphoma and Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 2931 KiB  
Review
Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
by Cristina Ferrari, Nicola Maggialetti, Tamara Masi, Anna Giulia Nappi, Giulia Santo, Artor Niccoli Asabella and Giuseppe Rubini
J. Pers. Med. 2021, 11(3), 217; https://doi.org/10.3390/jpm11030217 - 18 Mar 2021
Cited by 18 | Viewed by 4605
Abstract
Immunotherapy is a promising therapeutic strategy both for solid and hematologic tumors, such as in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). In particular, immune-checkpoint inhibitors, such as nivolumab and pembrolizumab, are increasingly used for the treatment of refractory/relapsed HL. At the same time, [...] Read more.
Immunotherapy is a promising therapeutic strategy both for solid and hematologic tumors, such as in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). In particular, immune-checkpoint inhibitors, such as nivolumab and pembrolizumab, are increasingly used for the treatment of refractory/relapsed HL. At the same time, evidence of chimeric antigen receptor (CAR)-T-cell immunotherapy efficacy mostly in NHL is growing. In this setting, the challenge is to identify an appropriate imaging method to evaluate immunotherapy response. The role of 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography/computed tomography (PET/CT), especially in early evaluation, is under investigation in order to guide therapeutic strategies, taking into account the possible atypical responses (hyperprogression and pseudoprogression) and immune-related adverse events that could appear on PET images. Herein, we aimed to present a critical overview about the role of 18F-FDG PET/CT in evaluating treatment response to immunotherapy in lymphoma patients. Full article
(This article belongs to the Special Issue Lymphoma and Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop